{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+Agent+Therapy&page=2", "query": { "intervention": "Single Agent Therapy", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+Agent+Therapy&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-23T19:13:26.426Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02336815", "title": "Selinexor Treatment of Refractory Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 202, "start_date": "2015-05-26", "completion_date": "2019-07-26", "has_results": true, "last_update_posted_date": "2023-01-26", "last_synced_at": "2026-09-23T19:13:26.426Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02336815" }, { "nct_id": "NCT06171685", "title": "MMRC Horizon One: RRMM (MMRC-099)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapse Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Teclistamab Monotherapy", "type": "DRUG" }, { "name": "Teclistamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Multiple Myeloma Research Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 300, "start_date": "2024-11-17", "completion_date": "2030-07-31", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-09-23T19:13:26.426Z", "location_count": 13, "location_summary": "Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06171685" }, { "nct_id": "NCT01334515", "title": "Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Neuroblastoma" ], "interventions": [ { "name": "hu14.18-IL2 fusion protein", "type": "BIOLOGICAL" }, { "name": "isotretinoin", "type": "DRUG" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 52, "start_date": "2011-09", "completion_date": "2019-09-30", "has_results": true, "last_update_posted_date": "2019-10-21", "last_synced_at": "2026-09-23T19:13:26.426Z", "location_count": 71, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Arcadia, California + 62 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Arcadia", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01334515" }, { "nct_id": "NCT00087035", "title": "Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "erlotinib hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "MALE", "summary": "65 Years and older · Male only" }, "enrollment_count": 1, "start_date": "2004-05", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2020-08-03", "last_synced_at": "2026-09-23T19:13:26.426Z", "location_count": 3, "location_summary": "Los Angeles, California • Seattle, Washington", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00087035" }, { "nct_id": "NCT02382640", "title": "Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Febuxostat XR", "type": "DRUG" }, { "name": "Maalox Advance Regular Strength liquid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 36, "start_date": "2015-03", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2016-04-29", "last_synced_at": "2026-09-23T19:13:26.426Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02382640" }, { "nct_id": "NCT04640168", "title": "Adaptive COVID-19 Treatment Trial 4 (ACTT-4)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Remdesivir", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 1010, "start_date": "2020-12-02", "completion_date": "2021-06-18", "has_results": true, "last_update_posted_date": "2022-06-28", "last_synced_at": "2026-09-23T19:13:26.426Z", "location_count": 61, "location_summary": "Birmingham, Alabama • Fresno, California • La Jolla, California + 50 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04640168" }, { "nct_id": "NCT01358968", "title": "A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "LY2603618", "type": "DRUG" }, { "name": "Desipramine", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2011-06", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2018-10-25", "last_synced_at": "2026-09-23T19:13:26.426Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01358968" }, { "nct_id": "NCT05255276", "title": "PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Adults" ], "interventions": [ { "name": "Sitravatinib 50 mg", "type": "DRUG" }, { "name": "Sitravatinib 100 mg", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 36, "start_date": "2022-02-02", "completion_date": "2023-02-10", "has_results": false, "last_update_posted_date": "2024-05-08", "last_synced_at": "2026-09-23T19:13:26.426Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05255276" }, { "nct_id": "NCT04585750", "title": "The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Advanced Malignant Neoplasm", "Metastatic Cancer", "Metastatic Solid Tumor", "Lung Cancer", "Ovarian Cancer", "Endometrial Cancer", "Prostate Cancer", "Colorectal Cancer", "Breast Cancer", "Other Cancer", "Locally Advanced", "Head and Neck Cancer", "Gall Bladder Cancer", "Small Cell Lung Cancer", "Small Cell Lung Cancer ( SCLC )", "Small Cell Lung Carcinoma", "NSCLC", "NSCLC (Non-small Cell Lung Cancer)", "SCLC", "Non-Small Cell Lung Carcinoma", "Triple Negative Breast Cancer", "TNBC", "HER2+ Breast Cancer", "Non-Small Cell Lung Cancer", "ER/PR Positive Breast Cancer", "HER2- Breast Cancer", "HER2-positive Breast Cancer", "HER2-negative Breast Cancer", "ER/PR(+), Her2(-) Breast Cancer" ], "interventions": [ { "name": "rezatapopt", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PMV Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 300, "start_date": "2020-10-29", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-09-23T19:13:26.426Z", "location_count": 33, "location_summary": "Irvine, California • La Jolla, California • Los Angeles, California + 27 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04585750" }, { "nct_id": "NCT06421935", "title": "M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "M9466", "type": "DRUG" }, { "name": "Tuvusertib", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone/Prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2024-08-07", "completion_date": "2027-02-22", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-09-23T19:13:26.426Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06421935" } ] }